Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma

NCT05113342 is registered in ClinicalTrials.gov with Cartesian Therapeutics as lead sponsor.

NCT NCT05113342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05113342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Cartesian Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
November 25, 2021
Completion date
November 8, 2024
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, relapse multiple myeloma